Artigos com autorizações de acesso público - Deepa RangachariSaiba mais
1 artigo não disponível publicamente
Trastuzumab Deruxtecan in Non–Small-Cell Lung Cancer
H Viray, D Rangachari, DB Costa
The New England journal of medicine 386 (18), 1769, 2022
Autorizações: US National Institutes of Health
51 artigos disponíveis publicamente
Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers
D Rangachari, N Yamaguchi, PA VanderLaan, E Folch, A Mahadevan, ...
Lung cancer 88 (1), 108-111, 2015
Autorizações: US National Institutes of Health
Combination olaparib and temozolomide in relapsed small-cell lung cancer
AF Farago, BY Yeap, M Stanzione, YP Hung, RS Heist, JP Marcoux, ...
Cancer discovery 9 (10), 1372-1387, 2019
Autorizações: US National Institutes of Health, Howard Hughes Medical Institute, German …
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes
PA VanderLaan, D Rangachari, SM Mockus, V Spotlow, HV Reddi, ...
Lung cancer 106, 17-21, 2017
Autorizações: US National Institutes of Health
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches
M Shea, DB Costa, D Rangachari
Therapeutic advances in respiratory disease 10 (2), 113-129, 2016
Autorizações: US National Institutes of Health
Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival
GJ Arnaoutakis, D Rangachari, DA Laheru, CA Iacobuzio-Donahue, ...
Journal of Gastrointestinal Surgery 15 (9), 1611-1617, 2011
Autorizações: US National Institutes of Health
Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3–PD-L1≥ 50% expression in lung adenocarcinoma
D Rangachari, PA VanderLaan, M Shea, X Le, MS Huberman, ...
Journal of thoracic oncology 12 (5), 878-883, 2017
Autorizações: US National Institutes of Health
Association of performance status with survival in patients with advanced non–small cell lung cancer treated with pembrolizumab monotherapy
K Sehgal, RR Gill, P Widick, P Bindal, DC McDonald, M Shea, ...
JAMA network open 4 (2), e2037120-e2037120, 2021
Autorizações: US National Institutes of Health
Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non–small cell lung cancer
L Ostios-Garcia, J Faig, GC Leonardi, AE Adeni, SJ Subegdjo, CA Lydon, ...
Journal of Thoracic Oncology 13 (7), 1037-1042, 2018
Autorizações: US National Institutes of Health
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
SE Jorge, S Schulman, JA Freed, PA VanderLaan, D Rangachari, ...
Lung cancer 90 (3), 369-374, 2015
Autorizações: US National Institutes of Health
Integrating palliative care in oncology: the oncologist as a primary palliative care provider
D Rangachari, TJ Smith
The Cancer Journal 19 (5), 373-378, 2013
Autorizações: US National Institutes of Health
EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M/C797S in …
D Rangachari, C To, JE Shpilsky, PA VanderLaan, SS Kobayashi, ...
Journal of Thoracic Oncology 14 (11), 1995-2002, 2019
Autorizações: US National Institutes of Health
EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation that displays sensitivity to approved and in-development lung cancer EGFR tyrosine kinase inhibitors
PENS Vasconcelos, C Gergis, H Viray, A Varkaris, M Fujii, D Rangachari, ...
JTO clinical and research reports 1 (3), 100051, 2020
Autorizações: US Department of Defense, US National Institutes of Health
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non–small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell …
VF Torous, D Rangachari, BP Gallant, M Shea, DB Costa, ...
Journal of the American Society of Cytopathology 7 (3), 133-141, 2018
Autorizações: US National Institutes of Health
Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors
RK Leaf, C Ferreri, D Rangachari, J Mier, W Witteles, G Ansstas, ...
American journal of hematology 94 (5), 563-574, 2019
Autorizações: US National Institutes of Health
Tumor biomarker testing in non-small-cell lung cancer: a decade of change
PA VanderLaan, D Rangachari, A Majid, MS Parikh, SP Gangadharan, ...
Lung Cancer 116, 90-95, 2018
Autorizações: US National Institutes of Health
EGFR testing in advanced non–small-cell lung cancer, a mini-review
Y Sheikine, D Rangachari, DC McDonald, MS Huberman, ES Folch, ...
Clinical lung cancer 17 (6), 483-492, 2016
Autorizações: US National Institutes of Health
EGFR exon 20 insertion mutations display sensitivity to Hsp90 inhibition in preclinical models and lung adenocarcinomas
SE Jorge, AR Lucena-Araujo, H Yasuda, Z Piotrowska, GR Oxnard, ...
Clinical Cancer Research 24 (24), 6548-6555, 2018
Autorizações: US National Institutes of Health
Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors
K Sehgal, R Patell, D Rangachari, DB Costa
Translational cancer research 7 (Suppl 7), S779, 2018
Autorizações: US National Institutes of Health
Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
K Sehgal, A Varkaris, H Viray, PA VanderLaan, D Rangachari, DB Costa
Journal for immunotherapy of cancer 8 (1), 2020
Autorizações: US National Institutes of Health
As informações de publicação e financiamento são determinadas automaticamente por um programa de computador